The Expected Pattern
The most commonly reported side effects across this peptide class (nausea, constipation, vomiting, diarrhea, and abdominal discomfort) are consistent with how the peptide acts on the gut. Their presence at low or moderate intensity is consistent with the mechanism.
Their absence isn't evidence of higher product quality. Their presence in the expected GI pattern isn't evidence of lower product quality. The studies reported these side effects at the rates they reported them across multiple separately-manufactured batches of the same molecule.
What the Pattern Means
Side effects are signals to interpret, not verdicts on the product. The threshold worth knowing has three parts: a baseline understanding of what the expected GI pattern looks like during dose-up, plus a clear sense of when something is no longer the routine pattern, plus clinician access to translate symptoms into action.
What this means
References3 sources
How to read these sources
This article uses primary sources and reviews to separate mechanism, human evidence, and context.
- Official Label
FDA-approved prescribing information (Wegovy)
U.S. Food and Drug Administration / Novo NordiskWEGOVY (semaglutide) prescribing information: 6 Adverse Reactions Read source
Used Here ForGrounding the side-effects question in the approved label's documented adverse-reaction rates for a legitimate product.
Good ForThe FDA-approved facts on expected side-effect rates for a properly manufactured GLP-1 drug.
Not ForPredicting a specific person's side-effect experience or severity.
FDA-approved labeling, DailyMed (National Library of Medicine), updated June 18, 2026 - Human Trial
Diabetes & Metabolism
ElsevierSemaglutide 2.4 mg in French people living with Class 3 obesity and comorbidities: Baseline characteristics and real-world safety data Read source
Used Here ForShowing that side effects occur even with a properly manufactured, regulated product in a high-risk population.
Good ForHuman tolerability evidence in a high-risk patient population.
Not ForGeneralizing to people without comorbidities or predicting an individual's reaction.
Diabetes & Metabolism 51(3):101625 - Human Trial
Massachusetts Medical SocietyTirzepatide Once Weekly for the Treatment of Obesity Read source
Used Here ForShowing GI adverse-event rates across dose bands in a well-controlled trial of an approved product.
Good ForHuman trial-measured GI side-effect frequency across doses.
Not ForConcluding side effects alone indicate a poor-quality or counterfeit product.
New England Journal of Medicine 387(3):205-216